Pages that link to "Q37118974"
Jump to navigation
Jump to search
The following pages link to Implications of EGFR PharmDx kit for cetuximab eligibility (Q37118974):
Displaying 8 items.
- Theranostic applications of antibodies in oncology. (Q27693293) (← links)
- Targeted therapies in colorectal cancer-an integrative view by PPPM (Q36646911) (← links)
- Personalized medicine and the clinical laboratory. (Q36916966) (← links)
- Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment (Q36958365) (← links)
- Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer (Q37316037) (← links)
- Roles of pathologists in molecular targeted cancer therapy (Q37627937) (← links)
- The evolution of phase I trials in cancer medicine: a critical review of the last decade (Q37953478) (← links)
- Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10 (Q39399928) (← links)